Search results for " PSYCHOSIS"

showing 10 items of 120 documents

Duration of active psychosis and functional outcomes in first-episode non-affective psychosis.

2018

AbstractBackground:The duration of untreated psychosis (DUP) has been associated with negative outcomes in psychosis; however, few studies have focused on the duration of active psychotic symptoms after commencing treatment (DAT). In this study, we aimed to evaluate the effect of DUP and DAT on functional long-term outcomes (3 years) in patients with early psychosis.Methods:We evaluated the Scale for the Assessment of Positive Symptoms (SAPS) at frequent intervals for 3 years after presentation to determine the DAT for 307 individuals with first-episode psychosis together with DUP and clinical variables. The functional outcomes were assessed using the Disability Assessment Scale (DAS) at th…

AdultMalePsychosismedicine.medical_specialtyTime FactorsLogistic regressionCohort Studies03 medical and health sciencesDisability Evaluation0302 clinical medicineActivities of Daily LivingmedicineHumansProspective StudiesPsychiatryProspective cohort studyFirst episodePsychiatric Status Rating ScalesReceiver operating characteristicbusiness.industrymedicine.disease030227 psychiatryPsychiatry and Mental healthTreatment OutcomePsychotic DisordersSchizophreniaNon affective psychosisdupSchizophreniaFemaleSchizophrenic PsychologybusinessSocial Adjustment030217 neurology & neurosurgeryAntipsychotic AgentsEuropean psychiatry : the journal of the Association of European Psychiatrists
researchProduct

The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI s…

2021

Premorbid functioning and cognitive measures may reflect gradients of developmental impairment across diagnostic categories in psychosis. In this study, we sought to examine the associations of current cognition and premorbid adjustment with symptom dimensions in a large first episode psychosis (FEP) sample. We used data from the international EU-GEI study. Bifactor modelling of the Operational Criteria in Studies of Psychotic Illness (OPCRIT) ratings provided general and specific symptom dimension scores. Premorbid Adjustment Scale estimated premorbid social (PSF) and academic adjustment (PAF), and WAIS-brief version measured IQ. A MANCOVA model examined the relationship between symptom di…

PsychosisFirst episode psychosiscognitive domainsPremorbid Adjustment ScaleQUOCIENTE DE INTELIGÊNCIATransdiagnostic Premorbid adjustmentNEGATIVE SYMPTOMSArticlesymptom dimensionspremorbid adjustmentWORKING-MEMORYSecondary analysisFirst episode psychosisfirst episode psychosis1ST-EPISODE NONAFFECTIVE PSYCHOSISMedicineScopusCognitive domain[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Settore MED/25 - PsichiatriaBiological PsychiatryTransdiagnosticbusiness.industryWorking memoryConfoundingCognitive domainsCognitionBIPOLAR DISORDERSymptom dimensionsmedicine.diseaseGENE-ENVIRONMENT INTERACTIONSFirst episode psychosiCANNABIS USEPsychiatry and Mental healthSymptom dimensionPerceptual reasoningJCRIQSOCIAL COGNITIONtransdiagnosticPROCESSING-SPEEDNEURODEVELOPMENTAL TRAJECTORIES[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Premorbid adjustmentbusinessSCHIZOAFFECTIVE DISORDERClinical psychology
researchProduct

IQ differences between patients with first episode psychosis in London and Palermo reflect differences in patterns of cannabis use.

2019

Aims: Cognitive impairment is a possible indicator of neurodevelopmental impairment, but not all psychotic patients are cognitively compromised. It has been suggested that heavy cannabis use may precipitate psychosis in those who show no such compromise. This study compares two samples of patients with first-episode psychosis and their respective non-psychotic controls, in London (UK) and Palermo (Italy), and examines whether different patterns of cannabis use are reflected in differences in IQ. Methods: The two studies used the same inclusion/exclusion criteria and instruments. The sample comprised 249 subjects from London (106 patients and 143 controls) and 247 subjects from Palermo (120 …

AdultCross-Cultural ComparisonMalePsychosismedicine.medical_specialtyAdolescentIntelligenceNeurodevelopmentYoung Adult03 medical and health sciences0302 clinical medicineCognitionFirst episode psychosisLondonmedicineSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.HumansCognitive DysfunctionIn patientCannabiPsychiatryCognitive impairmentSettore MED/25 - PsichiatriaBiological PsychiatryMulticentric studybiologybusiness.industryConfoundingCognitionCannabis usemedicine.diseasebiology.organism_classification030227 psychiatryPsychiatry and Mental healthItalyPsychotic DisordersRisk factorsCase-Control StudiesFemaleMarijuana UseCannabisbusiness030217 neurology & neurosurgery
researchProduct

Abstract # 3128 Metabolic-inflammatory status as predictor of clinical outcome at 1-year follow-up in patients with first episode psychosis

2019

Metabolic abnormalities and peripheral inflammation have been increasingly reported in patients at their first episode of psychosis (FEP) and associated with increased mortality. However, the impact of an abnormal metabolic-inflammatory status on the psychiatric outcome of FEP is understudied. This study aimed 1) to combine metabolic and inflammatory variables in factors accounting for an overall metabolic-inflammatory status in FEP patients; 2) to explore the association between these factors and clinical outcome at 1 year. We recruited 43 FEP patients and 50 healthy controls (HC). At baseline (T1) we measured high sensitivity C-reactive protein (hsCRP) as inflammatory biomarker, and body …

First episodePsychosismedicine.medical_specialtyTreatment responsemedicine.diagnostic_testEndocrine and Autonomic Systemsbusiness.industryImmunology1 year follow upmedicine.diseaseBehavioral NeuroscienceFirst episode psychosisInternal medicineMedicineIn patientbusinessLipid profileBody mass indexBrain, Behavior, and Immunity
researchProduct

"Semmonen siitä tuli Hitlerinki hommista" : ihmissuhteiden merkitykset skitsofreenistyyppisen psykoosin yhteydessä

2004

functional characteristicscase studytapaustutkimusskitsofreniamielenterveyssosiaaliset verkostotpsykoositpsychodynamic frameworkschizophrenia-like nonaffective psychosissocial networkpsykodynamiikka
researchProduct

Cannabis consumption and the risk of psychosis

2017

Summary Objectives: Cannabis is the most widely used illicit drug globally and its use has been linked to an increased risk for psychotic disorders. An association between cannabis consumption and psychotic symptoms was consistently reported by several studies. This case-control study aimed to widen the current findings about the impact of cannabis exposure on the risk of psychosis, by investigating the pattern of cannabis consumption in a sample of first-episode of psychosis (FEP) patients compared to healthy controls. Material and methods: 68 individuals who presented for the first time to mental health services of Palermo (Italy) with an ICD-10 diagnosis of psychotic disorders and 74 hea…

Settore M-PSI/08 - Psicologia ClinicaSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.cannabis schizophrenia psychosis tetrahydrocannabinol drug and schizophreniaSettore MED/25 - Psichiatria
researchProduct

2020

Abstract Background The long-term effectiveness of antipsychotic maintenance treatment after first-episode psychosis (FEP) is contested. In this real-world observational study, we examined how cumulative exposure to antipsychotics within the first 5 years from FEP was associated with the 19-year outcome. Methods Finnish national registers were used to detect all patients who were hospitalized due to non-affective psychosis in the mid-1990s, and who were treatment naïve prior to the inclusion period (N = 1318). Generalized linear models with logit link function were used to estimate how cumulative exposure to antipsychotics within the first 5 years from onset was associated with mortality, w…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentCumulative Exposuremedicine.disease030227 psychiatry03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineSchizophreniaFirst episode psychosisMedicine030212 general & internal medicinebusinessAntipsychoticAssociation (psychology)PsychiatrySchizophrenia Bulletin Open
researchProduct

F99. FIRST EPISODE PSYCHOSIS PATIENTS WHO USED CANNABIS DEVELOP THEIR ILLNESS AT A SIGNIFICANTLY YOUNGER AGE THAN THOSE WHO NEVER USED CONSISTENTLY A…

2018

Abstract Background Patients presenting to psychiatric services with their first episode of psychosis (FEP) report higher rates of previous cannabis use than the general population (Donoghue et al., 2011; Myles, Myles and Large, 2016). Evidence suggested that patients suffering from psychosis with a history of cannabis use have an earlier age of onset of psychosis (AOP) than those who never used it (Di Forti et al., 2013). We aim to investigate if the reported association between use of cannabis and AOP is consistent across different countries, once having taken into account different patterns of cannabis use (i.e. frequency of use and age at first use). Methods We analysed data on patterns…

Psychiatry and Mental healthmedicine.medical_specialtyAbstractsYounger agePoster Session IIbiologybusiness.industryFirst episode psychosisMedicineCannabisbiology.organism_classificationbusinessPsychiatrySchizophrenia Bulletin
researchProduct

Social disadvantage and psychosis: a case control study on italian First-Episodes of Psychosis (FEP)

2014

Introduction: A growing body of literature suggests that people affected by psychotic disorders are more likely to be unemployed, tend to live alone, have a poor social network, and are not able to establish long-term relationships (Morgan et al., 2008). Aims: To investigate social disadvantage in a sample of first-episode of psychosis patients and geographically matched controls. Methods: The study sample consists of 52 healthy controls and 37 FEP who were assessed using the MRC Sociodemographic Schedules. Results: Preliminary results suggest that, consistently with the literature, cases are more exposed than controls to social disadvantage. They tend to reach a lower education degree (OR …

Social disadvantageSocial disadvantage; PsychosisSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.PsychosisSettore MED/25 - Psichiatria
researchProduct

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

2017

Marco Solmi,1,2 Andrea Murru,3 Isabella Pacchiarotti,3 Juan Undurraga,4,5 Nicola Veronese,2,6 Michele Fornaro,7,8 Brendon Stubbs,2,9–11 Francesco Monaco,2 Eduard Vieta,3 Mary V Seeman,12 Christoph U Correll,13,14 André F Carvalho2,15 1Neuroscience Department, University of Padua, 2Institute for Clinical Research and Education in Medicine, Padua, Italy; 3Bipolar Disorders Unit, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain; 4Department of Psychiatry, Faculty of Medicine, Clínica Alemana Universidad del Desarrollo, 5Early Intervention Program, J. Horwitz Psychiatric Institute, Santiago, Chile; 6Na…

Olanzapinesafetymedicine.medical_specialtyside effectToxicology and Pharmaceutics (all)ReviewRM1-950psychosi03 medical and health sciencesIloperidonechemistry.chemical_compound0302 clinical medicineSertindoleJournal ArticlemedicineAsenapinePharmacology (medical)psychosisGeneral Pharmacology Toxicology and PharmaceuticstolerabilityPsychiatryLurasidoneBrexpiprazolePharmacologyChemical Health and Safetybusiness.industryMedicine (all)Transtornos PsicóticosGeneral Medicinepsychiatry3. Good health030227 psychiatryantipsychotics side effects tolerability safety psychosis psychiatryantipsychoticantipsychoticsside effectsPsychotic DisordersTolerabilitychemistryQuetiapineAntipsychotics; Psychiatry; Psychosis; Safety; Side effects; Tolerability; Medicine (all); Safety Research; Pharmacology Toxicology and Pharmaceutics (all); Chemical Health and Safety; Pharmacology (medical)Therapeutics. PharmacologyAntipsicóticosbusinessSafety Research030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugTherapeutics and Clinical Risk Management
researchProduct